Quick Answer
BioXcel Therapeutics, Inc. reported Total Revenue of $642.0 thousand for the year ending 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -71.7% in Total Revenue from 2024 to 2025.
- This data is from BioXcel Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $0.00 | Q2 2017: $0.00 | Q3 2017: $0.00 | Q1 2018: $0.00 | Q2 2018: $0.00 | Q3 2018: $0.00 | Q3 2022: $137.0 thousand | Q1 2023: $206.0 thousand | Q2 2023: $457.0 thousand | Q3 2023: $341.0 thousand | Q1 2024: $582.0 thousand | Q2 2024: $1.10 million | Q3 2024: $214.0 thousand | Q1 2025: $168.0 thousand | Q2 2025: $120.0 thousand | Q3 2025: $98.0 thousand.
- Over the full 4 years of available data (2022 to 2025), BioXcel Therapeutics, Inc.'s Total Revenue has grown by 71.2%.
- Historical annual values: Fiscal year 2025: $642.0 thousand | Fiscal year 2024: $2.27 million | Fiscal year 2023: $1.38 million | Fiscal year 2022: $375.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: